The economic burden of antimicrobial resistance (AMR) significantly exceeds the confines of the clinical world, with lasting repercussions for a society's health and financial systems, as explained by Kevin Outterson, a professor at Boston University and founding executive director of CARB-X, in a recent interview with Infection Control Today®(ICT®). The conversation unveiled a critical discrepancy…